MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
28.00
+0.05 (0.18%)
Mar 13, 2026, 4:00 PM EDT - Market closed
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,380,492
Market Cap
1.33B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Sep 30, 2024 | 38 | 11 | 40.74% |
| Jun 30, 2024 | 36 | - | - |
| Mar 31, 2024 | 28 | - | - |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Capricor Therapeutics | 160 |
| Precigen | 143 |
| Zenas BioPharma | 130 |
| Pharvaris | 118 |
| AtaiBeckley | 99 |
MBX News
- 2 days ago - MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 days ago - MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - GlobeNewsWire
- 5 days ago - CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - GlobeNewsWire
- 5 days ago - MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - GlobeNewsWire
- 19 days ago - MBX Biosciences to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 4 weeks ago - Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - MBX Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair - GlobeNewsWire